Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer
Adult
Male
Lung Neoplasms
QH301-705.5
Medizin
610
Antineoplastic Agents
Apoptosis
Disease-Free Survival
Gene Expression Regulation, Enzymologic
Cohort Studies
Mice
03 medical and health sciences
Carcinoma, Non-Small-Cell Lung
Animals
Humans
Biology (General)
Pyridoxal Kinase
Aged
Aged, 80 and over
0303 health sciences
Middle Aged
Vitamin B 6
Neoplasm Proteins
3. Good health
Survival Rate
Gene Expression Regulation, Neoplastic
Female
Cisplatin
Genome-Wide Association Study
DOI:
10.1016/j.celrep.2012.06.017
Publication Date:
2012-07-26T15:26:23Z
AUTHORS (69)
ABSTRACT
Patients with non-small cell lung cancer (NSCLC) are routinely treated with cytotoxic agents such as cisplatin. Through a genome-wide siRNA-based screen, we identified vitamin B6 metabolism as a central regulator of cisplatin responses in vitro and in vivo. By aggravating a bioenergetic catastrophe that involves the depletion of intracellular glutathione, vitamin B6 exacerbates cisplatin-mediated DNA damage, thus sensitizing a large panel of cancer cell lines to apoptosis. Moreover, vitamin B6 sensitizes cancer cells to apoptosis induction by distinct types of physical and chemical stress, including multiple chemotherapeutics. This effect requires pyridoxal kinase (PDXK), the enzyme that generates the bioactive form of vitamin B6. In line with a general role of vitamin B6 in stress responses, low PDXK expression levels were found to be associated with poor disease outcome in two independent cohorts of patients with NSCLC. These results indicate that PDXK expression levels constitute a biomarker for risk stratification among patients with NSCLC.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (55)
CITATIONS (112)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....